TPP1 Inhibitors
1 drugsAbout TPP1
Tripeptidyl peptidase-1 (TPP1) is a protein target under investigation for novel therapeutics, though its precise mechanisms of action are still being explored.
Currently, there is no genetic evidence directly linking TPP1 mutations to specific diseases, highlighting the need for further research to elucidate its role in disease pathogenesis.
TPP1 is the target of one FDA-approved biologic drug, BRINEURA, developed by BIOMARIN PHARM for a single indication outside major categories like cancer or diabetes.
Top TPP1 Drugs
BIOMARIN PHARM is the only company with an approved drug targeting TPP1.
The market is highly concentrated, suggesting high barriers to entry or limited commercial interest.
TPP1 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets TPP1, using enzyme modality.
The lack of modality diversity indicates a whitespace opportunity for small molecule or other therapeutic approaches.
TPP1 Clinical Trials 1 trial
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on TPP1. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 0 | 0 | 1 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
TPP1 Drug Approval Timeline (2017 - 2017)
The first and only drug, BRINEURA, was approved in 2017.
The approval timeline shows no recent activity, indicating potential saturation or lack of further development.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 1 (0 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on TPP1. A trial counts if an approved drug acting on TPP1 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.